Developer docs
API playgroundTry for free, no card

Search company profiles

Innogenetics

Full company profile

uuid000p1j2

Namestring
Innogenetics
Legal namestring
Fujirebio Holdings, Inc.
Company typeenum
Private
Founded yearint
1970
Descriptiontext

Innogenetics is a Belgian specialty diagnostics company founded in 1985 in Gent, focused on developing diagnostic products and therapies for infectious diseases. The company built a portfolio of manual and semi-automated immunoassay and line probe test kits (branded INNO-LIA, INNO-LiPA, and INNOTEST) used in clinical laboratories for infectious disease and other diagnostic applications. Following its 2010 acquisition by Fujirebio (a wholly-owned subsidiary of Japan's H.U. Group Holdings Inc.), Innogenetics became the nucleus of Fujirebio Europe N.V., also based in Ghent, and its product lines were retained as sub-brands within the larger IVD portfolio. Today, the Gent-based operations contribute diagnostic content, biomarker expertise, and R&D capabilities to the parent's broader biomarker-to-IVD platform, including neurological disease testing (Alzheimer's, MS, Parkinson's, ALS) and the CDMO services offered by the group.

The business model of the parent group (Fujirebio) combines one-time sales of instruments and assay kits (Lumipulse G, INNO-LIA Score, CanAg, INNO-LiPA, INNOTEST, controls, antibodies/antigens), recurring revenue from CDMO and OEM partnerships with other diagnostic technology providers, and subscription-style revenue from LIRAS interpretation software. The Ghent operations are central to the European arm of this model, supplying infectious disease and neurological biomarker content, supporting clinical and regulatory services, and serving as the integration point for the 2026 ADx NeuroSciences consolidation. Innogenetics' customer base is not separately disclosed; within the broader Fujirebio group, end-customers include hospital and reference laboratories, CDMO partners (e.g., the announced Alzinova collaboration), and channel partners such as Sysmex, while broader disease segments served include autoimmune, cardiac, oncology, transplantation, and infectious diseases.

Short descriptiontext

Innogenetics is a Belgian specialty diagnostics company founded in 1985 in Gent, developing diagnostic products and therapies for infectious diseases. Since its 2010 acquisition by Fujirebio, it operates as the basis of Fujirebio Europe N.V., contributing INNO-LIA, INNO-LiPA, and INNOTEST diagnostic kits and biomarker R&D to the parent's global IVD and CDMO portfolio.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersGent, Belgium
HQ citystring
Gent
HQ countrystring
Belgium
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
infectious disease diagnostics, specialty diagnostics products, biotechnology therapies, diagnostic test development, in vitro diagnostics
Industry3 codes
PRIMARYHLAHAAAC
Microbiology & Infectious Disease Diagnostics (Culture/ID/AST)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Infectious Disease Diagnostics
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1IVD Products and Kits
TypeOne Time License
Description

Sale of instruments (LUMIPULSE G, TENDIGO, RoboBlot, Auto-LIA, Auto-LiPA), kits for fully automated testing (Lumipulse G and INNO-LIA Score assays), manual/semi-automated testing kits (CanAg, INNO-LIA, INNO-LiPA, INNOTEST), controls, and raw materials (antibodies and antigens)

fujirebio.com
2CDMO/Contract Services
TypeProfessional Services
Description

Revenue from Contract Development & Manufacturing Organization partnerships providing development, manufacturing, and clinical and regulatory services to other technology providers. Reinvests revenues from these partnerships into further R&D to fuel innovation engine.

fujirebio.com
3Software Solutions
TypeSubscription Recurring
Description

LIRAS software solutions for reading and interpretation of diagnostic tests

fujirebio.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 9 records shown
1Lumipulse
Description

Fully automated testing platform for biomarkers including FDA-cleared neurological tests

fujirebio.com
+8 more records
Core offering1 text field

Innogenetics is a specialty diagnostics company that develops therapies and diagnostic products for infectious diseases. Founded in 1985 and headquartered in Ghent, Belgium, the company operates as a biotech focused on infectious-disease diagnostics, and was acquired by Fujirebio in 2010, becoming part of the Fujirebio in vitro diagnostics organization.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Blood-based Alzheimer's disease diagnosis made a reality through FDA-cleared biomarkers
+2 more records
Product overview1 text field

Fujirebio is an in vitro diagnostics (IVD) company offering a comprehensive biomarker innovation and CDMO services portfolio. The company operates a biomarker-to-IVD journey spanning from pioneering research and scientific innovation through clinical validation on proprietary platforms to global CDMO partnerships. The core product portfolio includes: LUMIPULSE® G automated instruments paired with fully automated assay kits for neurodegenerative disease testing (pTau 217, NfL biomarkers for Alzheimer's disease); TENDIGO™, RoboBlot™, Auto-LIA™, and Auto-LiPA™ instruments for various testing needs; manual and semi-automated testing solutions (CanAg®, INNO-LIA®, INNO-LiPA®, INNOTEST®); LIRAS® software for reading and interpretation; and raw materials including antibodies and antigens. The company also offers CDMO services for contract development and manufacturing. Product categories span autoimmune diseases, bone metabolism, cardiac, diabetes, fertility, genetic disorders, hypertension, infectious diseases, inflammation, interstitial pneumonia, neurodegeneration, transplantation, and tumor markers.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2026-06-24
Description

Non-binding Letter of Intent signed for potential commercialization of blood-based Alzheimer's disease diagnostic test. Alzinova AB (publ) announced entering into LoI with Fujirebio regarding potential commercialization of their diagnostic test.

2ADx NeuroSciences
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-01
Description

Complete integration of ADx NeuroSciences N.V. into Fujirebio Europe N.V. organization (effective April 1, 2026). This completes a prior process of integration, unleashing new possibilities in neuro testing.

fujirebio.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-02-05
Description

Sales collaboration for dementia testing. Fujirebio and Sysmex began sales collaboration for dementia testing products. Fujirebio Holdings, Inc. is a consolidated subsidiary of H.U. Group Holdings Inc.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2025-06-23
Description

Acquisition of Plasma Services Group to strengthen position as provider of critical and high quality biological raw materials to the IVD and life science industries. Located in Malvern, PA, USA.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2025-06-05
Description

Strategic collaboration to advance infectious disease research. Fujirebio announced collaboration with Stanford Medicine (Palo Alto, CA) to advance infectious disease research.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Fujirebio is the parent company that acquired Innogenetics in 2010 and now commercializes Innogenetics-originated brands (INNO-LIA, INNO-LiPA, INNOTEST) alongside its own Lumipulse platform. It is the most direct corporate peer and now houses Innogenetics' product line within a global IVD portfolio.

TypeDirect peer
Description

bioMérieux is a global leader in in vitro diagnostics with deep specialization in microbiology and infectious disease testing (the same category Innogenetics serves). Its broad portfolio of culture, immunoassay, and molecular infectious-disease kits competes directly with Innogenetics' heritage product lines.

TypeDirect peer
Description

Hologic's Diagnostic Solutions division offers molecular diagnostics for infectious diseases (e.g., Panther system for HPV, CT/NG, viral load) — directly comparable to Innogenetics' specialty molecular and HPV testing franchise.

TypeDirect peer
Description

Cepheid's GeneXpert system is a leading molecular diagnostics platform for infectious disease (including HPV, MTB, MRSA). Comparable to Innogenetics' molecular infectious-disease focus and competes for the same hospital laboratory customers.

TypeDirect peer
Description

Qiagen provides sample-preparation technologies and molecular diagnostic kits for infectious disease and HPV testing. It overlaps with Innogenetics' molecular diagnostics heritage and competes in similar European and global hospital-lab channels.

TypeDirect peer
Description

DiaSorin specializes in immunodiagnostics and molecular diagnostics with a strong infectious-disease and HPV testing franchise, plus a growing neurodegenerative biomarker portfolio — closely aligned with Innogenetics' specialty diagnostics focus.

TypeDirect peer
Description

QuidelOrtho produces rapid and specialty diagnostics for infectious disease, including Sofia and Triage product lines. Comparable to Innogenetics in specialty infectious-disease diagnostics and serves overlapping hospital and reference-lab channels.

TypeBroad incumbent
Description

Roche Diagnostics is the global IVD market leader, with extensive infectious-disease, HPV, and now blood-based Alzheimer's (Elecsys pTau 217) assays. It competes broadly with both Innogenetics' heritage infectious-disease franchise and Fujirebio's neuro pipeline.

9Abbott Diagnostics
TypeBroad incumbent
Description

Abbott's diagnostics division operates ARCHITECT and Alinity platforms with broad infectious-disease and specialty testing menus. It is a broad incumbent competing with both Innogenetics' traditional assays and Fujirebio's automated Lumipulse platform.

TypeEmerging player
Description

Sekisui Diagnostics offers clinical chemistry and infectious-disease diagnostics, including specialty coagulation and infectious-disease kits. It is a niche IVD player comparable in size and scope to Innogenetics as a specialty diagnostics business unit.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment2 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Innogenetics

Infectious Disease Diagnosticsinnogenetics.com

Innogenetics is a Belgian specialty diagnostics company founded in 1985 in Gent, developing diagnostic products and therapies for infectious diseases. Since its 2010 acquisition by Fujirebio, it operates as the basis of Fujirebio Europe N.V., contributing INNO-LIA, INNO-LiPA, and INNOTEST diagnostic kits and biomarker R&D to the parent's global IVD and CDMO portfolio.

What Innogenetics does

Innogenetics is a Belgian specialty diagnostics company founded in 1985 in Gent, focused on developing diagnostic products and therapies for infectious diseases. The company built a portfolio of manual and semi-automated immunoassay and line probe test kits (branded INNO-LIA, INNO-LiPA, and INNOTEST) used in clinical laboratories for infectious disease and other diagnostic applications. Following its 2010 acquisition by Fujirebio (a wholly-owned subsidiary of Japan's H.U. Group Holdings Inc.), Innogenetics became the nucleus of Fujirebio Europe N.V., also based in Ghent, and its product lines were retained as sub-brands within the larger IVD portfolio. Today, the Gent-based operations contribute diagnostic content, biomarker expertise, and R&D capabilities to the parent's broader biomarker-to-IVD platform, including neurological disease testing (Alzheimer's, MS, Parkinson's, ALS) and the CDMO services offered by the group.

The business model of the parent group (Fujirebio) combines one-time sales of instruments and assay kits (Lumipulse G, INNO-LIA Score, CanAg, INNO-LiPA, INNOTEST, controls, antibodies/antigens), recurring revenue from CDMO and OEM partnerships with other diagnostic technology providers, and subscription-style revenue from LIRAS interpretation software. The Ghent operations are central to the European arm of this model, supplying infectious disease and neurological biomarker content, supporting clinical and regulatory services, and serving as the integration point for the 2026 ADx NeuroSciences consolidation. Innogenetics' customer base is not separately disclosed; within the broader Fujirebio group, end-customers include hospital and reference laboratories, CDMO partners (e.g., the announced Alzinova collaboration), and channel partners such as Sysmex, while broader disease segments served include autoimmune, cardiac, oncology, transplantation, and infectious diseases.

Innogenetics firmographics

Firmographics
Name
Innogenetics
Legal name
Fujirebio Holdings, Inc.
Website
https://innogenetics.com
Company type
Private
Founded year
1970
Operating status
Operating
Headcount range
11–50 employees
Short description
Innogenetics is a Belgian specialty diagnostics company founded in 1985 in Gent, developing diagnostic products and therapies for infectious diseases. Since its 2010 acquisition by Fujirebio, it operates as the basis of Fujirebio Europe N.V., contributing INNO-LIA, INNO-LiPA, and INNOTEST diagnostic kits and biomarker R&D to the parent's global IVD and CDMO portfolio.
Ownership category
akta.pro rank

Innogenetics industry classification

Industry
Product category
Infectious Disease Diagnostics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAHAAAC
Microbiology & Infectious Disease Diagnostics (Culture/ID/AST)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories

Keywords

  • Infectious disease diagnostics
  • Specialty diagnostics products
  • Biotechnology therapies
  • Diagnostic test development
  • In vitro diagnostics

Where Innogenetics is headquartered

Location

Headquarters

HQ city
Gent
HQ country
Belgium
HQ region
Europe

Offices2 records

Markets served

Innogenetics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain

Revenue model

  1. IVD Products and Kits: Sale of instruments (LUMIPULSE G, TENDIGO, RoboBlot, Auto-LIA, Auto-LiPA), kits for fully automated testing (Lumipulse G and INNO-LIA Score assays), manual/semi-automated testing kits (CanAg, INNO-LIA, INNO-LiPA, INNOTEST), controls, and raw materials (antibodies and antigens)
  2. CDMO/Contract Services: Revenue from Contract Development & Manufacturing Organization partnerships providing development, manufacturing, and clinical and regulatory services to other technology providers. Reinvests revenues from these partnerships into further R&D to fuel innovation engine.
  3. Software Solutions: LIRAS software solutions for reading and interpretation of diagnostic tests

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Innogenetics product offering

Product offering

Core offering

Innogenetics is a specialty diagnostics company that develops therapies and diagnostic products for infectious diseases. Founded in 1985 and headquartered in Ghent, Belgium, the company operates as a biotech focused on infectious-disease diagnostics, and was acquired by Fujirebio in 2010, becoming part of the Fujirebio in vitro diagnostics organization.

Product overview

Fujirebio is an in vitro diagnostics (IVD) company offering a comprehensive biomarker innovation and CDMO services portfolio. The company operates a biomarker-to-IVD journey spanning from pioneering research and scientific innovation through clinical validation on proprietary platforms to global CDMO partnerships. The core product portfolio includes: LUMIPULSE® G automated instruments paired with fully automated assay kits for neurodegenerative disease testing (pTau 217, NfL biomarkers for Alzheimer's disease); TENDIGO™, RoboBlot™, Auto-LIA™, and Auto-LiPA™ instruments for various testing needs; manual and semi-automated testing solutions (CanAg®, INNO-LIA®, INNO-LiPA®, INNOTEST®); LIRAS® software for reading and interpretation; and raw materials including antibodies and antigens. The company also offers CDMO services for contract development and manufacturing. Product categories span autoimmune diseases, bone metabolism, cardiac, diabetes, fertility, genetic disorders, hypertension, infectious diseases, inflammation, interstitial pneumonia, neurodegeneration, transplantation, and tumor markers.

Differentiator

Problem solved

Functional benefit

Brands

  • Lumipulse: Fully automated testing platform for biomarkers including FDA-cleared neurological tests
  • INNO-LIA
  • INNOTEST
  • CanAg
  • LIRAS
  • NExT (Neuro Expert Toolbox)
  • Lumipulse G NfL Blood assay
  • Lumipulse G pTau 217 Plasma assay
  • Lumipulse G pTau 217 CSF assay

Quantifiable outcome

  • Blood-based Alzheimer's disease diagnosis made a reality through FDA-cleared biomarkers
  • +2 more outcomes

Companies that use Innogenetics

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles1 record

Innogenetics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Innogenetics partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered strategic and core.

  • AlzinovastrategicStrategic or Co-development Partner · 24 June 2026Non-binding Letter of Intent signed for potential commercialization of blood-based Alzheimer's disease diagnostic test. Alzinova AB (publ) announced entering into LoI with Fujirebio regarding potential commercialization of their diagnostic test.
  • ADx NeuroSciencescoreStrategic or Co-development Partner · 1 April 2026Complete integration of ADx NeuroSciences N.V. into Fujirebio Europe N.V. organization (effective April 1, 2026). This completes a prior process of integration, unleashing new possibilities in neuro testing.
  • SysmexcoreChannel Partner/ Reseller/ Distributor · 5 February 2026Sales collaboration for dementia testing. Fujirebio and Sysmex began sales collaboration for dementia testing products. Fujirebio Holdings, Inc. is a consolidated subsidiary of H.U. Group Holdings Inc.
  • Plasma Services GroupstrategicStrategic or Co-development Partner · 23 June 2025Acquisition of Plasma Services Group to strengthen position as provider of critical and high quality biological raw materials to the IVD and life science industries. Located in Malvern, PA, USA.
  • Stanford MedicinestrategicStrategic or Co-development Partner · 5 June 2025Strategic collaboration to advance infectious disease research. Fujirebio announced collaboration with Stanford Medicine (Palo Alto, CA) to advance infectious disease research.

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Innogenetics competitors and assessment

Company assessment

Broad incumbents

  • Fujirebio: Fujirebio is the parent company that acquired Innogenetics in 2010 and now commercializes Innogenetics-originated brands (INNO-LIA, INNO-LiPA, INNOTEST) alongside its own Lumipulse platform. It is the most direct corporate peer and now houses Innogenetics' product line within a global IVD portfolio.
  • Roche Diagnostics: Roche Diagnostics is the global IVD market leader, with extensive infectious-disease, HPV, and now blood-based Alzheimer's (Elecsys pTau 217) assays. It competes broadly with both Innogenetics' heritage infectious-disease franchise and Fujirebio's neuro pipeline.
  • Abbott Diagnostics: Abbott's diagnostics division operates ARCHITECT and Alinity platforms with broad infectious-disease and specialty testing menus. It is a broad incumbent competing with both Innogenetics' traditional assays and Fujirebio's automated Lumipulse platform.

Direct peers

  • bioMérieux: bioMérieux is a global leader in in vitro diagnostics with deep specialization in microbiology and infectious disease testing (the same category Innogenetics serves). Its broad portfolio of culture, immunoassay, and molecular infectious-disease kits competes directly with Innogenetics' heritage product lines.
  • Hologic: Hologic's Diagnostic Solutions division offers molecular diagnostics for infectious diseases (e.g., Panther system for HPV, CT/NG, viral load) — directly comparable to Innogenetics' specialty molecular and HPV testing franchise.
  • Cepheid (Danaher): Cepheid's GeneXpert system is a leading molecular diagnostics platform for infectious disease (including HPV, MTB, MRSA). Comparable to Innogenetics' molecular infectious-disease focus and competes for the same hospital laboratory customers.
  • Qiagen: Qiagen provides sample-preparation technologies and molecular diagnostic kits for infectious disease and HPV testing. It overlaps with Innogenetics' molecular diagnostics heritage and competes in similar European and global hospital-lab channels.
  • DiaSorin: DiaSorin specializes in immunodiagnostics and molecular diagnostics with a strong infectious-disease and HPV testing franchise, plus a growing neurodegenerative biomarker portfolio — closely aligned with Innogenetics' specialty diagnostics focus.
  • QuidelOrtho: QuidelOrtho produces rapid and specialty diagnostics for infectious disease, including Sofia and Triage product lines. Comparable to Innogenetics in specialty infectious-disease diagnostics and serves overlapping hospital and reference-lab channels.

Emerging players

  • Sekisui Diagnostics: Sekisui Diagnostics offers clinical chemistry and infectious-disease diagnostics, including specialty coagulation and infectious-disease kits. It is a niche IVD player comparable in size and scope to Innogenetics as a specialty diagnostics business unit.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Innogenetics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Innogenetics leadership team

Management profile

Number of profiles

Profiles1 record

Innogenetics subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Innogenetics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Innogenetics M&A and investment

M&A and investment

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Innogenetics

What does Innogenetics do?

Innogenetics is a specialty diagnostics company that develops therapies and diagnostic products for infectious diseases. Founded in 1985 and headquartered in Ghent, Belgium, the company operates as a biotech focused on infectious-disease diagnostics, and was acquired by Fujirebio in 2010, becoming part of the Fujirebio in vitro diagnostics organization.

Is Innogenetics a public or private company?

Innogenetics is a private company. It is classified as corporate owned and is currently operating.

When was Innogenetics founded?

Innogenetics was founded in 1970. It employs 11 to 50 people.

Where is Innogenetics based?

Innogenetics is headquartered in Gent, Belgium, in the Europe region.

How does Innogenetics make money?

Three revenue lines are on record. IVD Products and Kits are the primary driver. The others are CDMO/Contract Services and software Solutions.

Who are Innogenetics's main competitors?

Broad incumbents on record are Fujirebio, Roche Diagnostics and Abbott Diagnostics. Direct peers are bioMérieux, Hologic, Cepheid (Danaher), Qiagen, DiaSorin and QuidelOrtho. Sekisui Diagnostics is listed as an emerging player.

Does Innogenetics have an API?

No public API is recorded for Innogenetics.

What industry is Innogenetics in?

Innogenetics's product category is Infectious Disease Diagnostics. Its primary akta.pro industry code is HLAHAAAC, Microbiology & Infectious Disease Diagnostics (Culture/ID/AST), with a secondary code of HLAHAAAD, Molecular Diagnostics (PCR/NAAT/NGS-based IVD). Its NAICS code is 541714 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireInnogenetics Reports Results for the First Half of 2003 in Line with ExpectationsInnogenetics reported first-half 2003 results with product sales up 16% to €27.5 million and a gross margin of 54.5%. R&D expenses rose 22% to €15.7 million, and the company posted an operating loss of €10.0 million. CEO Philippe Archinard said Diagnostics progress met 2003 plans and expects higher license fee income in the second half.GlobeNewswireInnogenetics Reports Results for the First Quarter of 2003 in Line with ExpectationsInnogenetics reported Q1 2003 results with product sales up 13% to €13.6 million and a gross margin of 55.1%. R&D spending rose 15% to €7.2 million, and the company posted an operating loss of €4.1 million. Cash position stood at €32.1 million.GlobeNewswireInnogenetics Announces Positive Results in Pivotal Preclinical Study in SepsisInnogenetics reported positive preclinical results for its anti-inflammatory monoclonal antibody INNO 202 in a sepsis model, where six of eight treated animals survived 7 days versus all six controls dying. The company plans to pursue clinical trials for the drug.GlobeNewswireInnogenetics' Outlook for 2003 -- Enhanced Financial Prospects and Promising New Therapeutic DevelopmentsInnogenetics announced preliminary 2002 results showing a profitable diagnostics division with 15% sales growth and a strong cash position. It outlined a 2003 outlook with 15-20% revenue growth and reduced cash burn, and reported positive Phase IIa results for its hepatitis C therapeutic vaccine. Clinical trials for the vaccine and other programs are ongoing.GlobeNewswireInnogenetics Announces Positive Liver Histology Results of Its Hepatitis C Therapeutic VaccineInnogenetics announced liver biopsy results from its hepatitis C vaccine trial, showing 79% of patients had stable or improved histology scores. The vaccine halted fibrosis progression, but HCV-RNA levels remained detectable. Final results are expected before year-end.